{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(10)"],"submitter":["Gordon MS"],"funding":["AbbVie"],"pubmed_abstract":["Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25-7.5 mg/kg) until progressive disease or unacceptable toxicity. As of August 2018, 55 patients with solid tumors were enrolled in the dilpacimab monotherapy dose-escalation and dose-expansion cohorts. The most common treatment-related adverse events (TRAE) included hypertension (60.0%), headache (30.9%), and fatigue "],"journal":["Molecular cancer therapeutics"],"pagination":["1988-1995"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9398147"],"repository":["biostudies-literature"],"pubmed_title":["Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors."],"pmcid":["PMC9398147"],"pubmed_authors":["Motwani M","Kasichayanula S","Hamilton EP","Blaney M","Ramanathan RK","Yue H","Morgan-Lappe SE","Wang L","Barve M","Wainberg ZA","Nemunaitis J","Naumovski L","Sledge GW","Strickler JH","Gordon MS"],"additional_accession":[]},"is_claimable":false,"name":"Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.","description":"Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25-7.5 mg/kg) until progressive disease or unacceptable toxicity. As of August 2018, 55 patients with solid tumors were enrolled in the dilpacimab monotherapy dose-escalation and dose-expansion cohorts. The most common treatment-related adverse events (TRAE) included hypertension (60.0%), headache (30.9%), and fatigue ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-04T13:08:39.661Z","creation":"2025-04-04T13:08:39.661Z"},"accession":"S-EPMC9398147","cross_references":{"pubmed":["34315767"],"doi":["10.1158/1535-7163.MCT-20-0985"]}}